Sign in Subscribe
HIV

Groundbreaking HIV Prevention: Lenacapavir Injection Shows Exceptional Efficacy in Various Demographics

Strategic Insights

— 1 min read

WHO recently welcomed the findings of the PURPOSE-2 trial, an interim analysis of which demonstrated a remarkable 96% reduction in the risk of acquiring HIV among participants who received long-acting injectable lenacapavir (LEN). This HIV-1 capsid inhibitor, administered subcutaneously twice a year, was found to be highly effective in preventing HIV among cisgender men, transgender men, transgender women, and gender non-binary individuals who have sex with partners assigned male at birth. With 99.9% of individuals using LEN not acquiring HIV, the trial highlights the potential of LEN to transform HIV prevention globally.

Key Takeaways:

  • The PURPOSE-2 trial, conducted in Argentina, Brazil, Mexico, Peru, South Africa, Thailand, and the United States, enrolled 3267 participants, including cisgender men, transgender men, transgender women, and gender non-binary individuals aged 16 and older.
  • Participants were randomized to receive either twice-yearly subcutaneous injections of LEN or daily oral TDF/FTC, with 2180 participants receiving LEN and 1087 participants receiving daily oral TDF/FTC.
  • LEN demonstrated a 96% reduction in HIV incidence compared to background HIV incidence (2.37 per 100 person-years), and was 89% more effective than daily oral TDF/FTC in preventing HIV acquisition.
  • Among 2180 participants receiving LEN twice-yearly, only two new HIV cases were recorded, while nine new cases were recorded among the 1087 participants receiving daily oral TDF/FTC.
  • LEN showed a 96% reduction in the risk of acquiring HIV among study participants, with 99.9% of individuals using LEN not acquiring HIV.
  • The trial highlights the potential of LEN to transform HIV prevention globally, particularly in regions and communities with high HIV incidence, and emphasizes the need for accessible and equitable global access to this new HIV prevention tool.

Statistics:

  • 3267 participants were enrolled in the PURPOSE-2 trial.
  • 2180 participants received LEN twice-yearly subcutaneous injections.
  • 1087 participants received daily oral TDF/FTC.
  • 99.9% of individuals using LEN did not acquire HIV.
  • Only two new HIV cases were recorded among participants receiving LEN.
  • Nine new HIV cases were recorded among participants receiving daily oral TDF/FTC.
  • LEN demonstrated a 96% reduction in HIV incidence compared to background HIV incidence (2.37 per 100 person-years).
  • LEN was 89% more effective than daily oral TDF/FTC in preventing HIV acquisition.

Sources:

  • WHO: [Category: Pharmaceuticals, Health Care, Clinical Trials]
  • [www.purposestudies.com]

Read more